Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BRD9 is essential for ribosome biogenesis and survival of multiple myeloma cells.

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE197492 | GEO | 2023/02/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.

Project description:PurposeBRD9 is a defining component of the noncanonical SWI/SNF complex, which regulates gene expression by controlling chromatin dynamics. Although recent studies have found an oncogenic role for BRD9 in multiple cancer types including multiple myeloma, its clinical significance and oncogenic mechanism have not yet been elucidated. Here, we sought to identify the clinical and biological impact of BRD9 in multiple myeloma, which may contribute to the development of novel therapeutic strategies.Experimental designWe performed integrated analyses of BRD9 in vitro and in vivo using multiple myeloma cell lines and primary multiple myeloma cells in established preclinical models, which identified the molecular functions of BRD9 contributing to multiple myeloma cell survival.ResultsWe found that high BRD9 expression was a poor prognostic factor in multiple myeloma. Depleting BRD9 by genetic (shRNA) and pharmacologic (dBRD9-A; proteolysis-targeting chimera; BRD9 degrader) approaches downregulated ribosome biogenesis genes, decreased the expression of the master regulator MYC, and disrupted the protein-synthesis maintenance machinery, thereby inhibiting multiple myeloma cell growth in vitro and in vivo in preclinical models. Importantly, we identified that the expression of ribosome biogenesis genes was associated with the disease progression and prognosis of patients with multiple myeloma. Our results suggest that BRD9 promotes gene expression by predominantly occupying the promoter regions of ribosome biogenesis genes and cooperating with BRD4 to enhance the transcriptional function of MYC.ConclusionsOur study identifies and validates BRD9 as a novel therapeutic target in preclinical models of multiple myeloma, which provides the framework for the clinical evaluation of BRD9 degraders to improve patient outcome.

| S-EPMC10150249 | biostudies-literature

BRD9 is essential for ribosome biogenesis and survival of multiple myeloma cells.

Project description:BRD9 is essential for ribosome biogenesis and survival of multiple myeloma cells.

| PRJNA810599 | ENA

Multiple myeloma

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-01-24 | GSE125364 | GEO

Post-transcriptional regulation of Ribosome Biogenesis

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-08-03 | GSE231980 | GEO

Multiple mechanisms disrupt let-7 miRNA biogenesis and function in neuroblastoma

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-07-06 | E-GEOD-81500 | biostudies-arrayexpress

The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis.

Project description:The orphan small nucleolar RNA (snoRNA) ACA11 is overexpressed as a result of the t(4;14) chromosomal translocation in multiple myeloma (MM), increases reactive oxygen species, and drives cell proliferation. Like other snoRNAs, ACA11 is predominantly localized to a sub-nuclear organelle, the nucleolus. We hypothesized that increased ACA11 expression would increase ribosome biogenesis and protein synthesis. We found that ACA11 overexpression in MM cells increased nucleolar area and number as well as silver-binding nucleolar organizing regions (AgNORs). Supporting these data, samples from t(4;14)-positive patients had higher AgNORs scores than t(4;14)-negative samples. ACA11 also upregulated ribosome production, pre-47S rRNA synthesis, and protein synthesis in a ROS-dependent manner. Lastly, ACA11 overexpression enhanced the response to proteasome inhibitor in MM cells, while no effect was found in response to high doses of melphalan. Together, these data demonstrate that ACA11 stimulates ribosome biogenesis and influences responses to chemotherapy. ACA11 may be a useful target to individualize the treatment for t(4;14)-positive myeloma patients.

| S-EPMC6996358 | biostudies-literature

Post-transcriptional regulation of Ribosome Biogenesis during differentiation

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-08-03 | GSE214875 | GEO

Multiple myeloma patients and control

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-10-06 | GSE159232 | GEO

Gene expression signature predicting post-relapse survival of myeloma patients identified by co-culture of myeloma cells with osteoclasts and osteoblast progenitors

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-08-13 | E-GEOD-31162 | biostudies-arrayexpress

p53 activation during ribosome biogenesis regulates normal erythroid differentiation.

Project description:This SuperSeries is composed of the SubSeries listed below.